Harmony Biosciences Holdings (HRMY) Short term Debt (2021 - 2025)
Harmony Biosciences Holdings (HRMY) has disclosed Short term Debt for 5 consecutive years, with $20.0 million as the latest value for Q4 2025.
- Quarterly Short term Debt rose 23.08% to $20.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $20.0 million through Dec 2025, up 23.08% year-over-year, with the annual reading at $20.0 million for FY2025, 23.08% up from the prior year.
- Short term Debt hit $20.0 million in Q4 2025 for Harmony Biosciences Holdings, roughly flat from $20.0 million in the prior quarter.
- In the past five years, Short term Debt ranged from a high of $20.0 million in Q3 2025 to a low of $2.0 million in Q3 2021.
- Historically, Short term Debt has averaged $10.9 million across 5 years, with a median of $15.0 million in 2023.
- Biggest five-year swings in Short term Debt: changed 0.0% in 2022 and later soared 650.0% in 2023.
- Year by year, Short term Debt stood at $2.0 million in 2021, then changed by 0.0% to $2.0 million in 2022, then skyrocketed by 650.0% to $15.0 million in 2023, then rose by 8.33% to $16.2 million in 2024, then increased by 23.08% to $20.0 million in 2025.
- Business Quant data shows Short term Debt for HRMY at $20.0 million in Q4 2025, $20.0 million in Q3 2025, and $18.8 million in Q2 2025.